Ordering Recommendation

Prognostication and monitoring in NSCLC.

Mnemonic
CYFRA
Methodology

Quantitative Enzyme-Linked Immunosorbent Assay

Performed

Wed

Reported

1-8 days
The level of CYFRA 21-1 cannot be used as absolute evidence for the presence or absence of disease.

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Plain red or serum separator tube.

Specimen Preparation

Allow serum specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma. Icteric, lipemic, or hemolyzed specimens.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 2 months (avoid repeated freeze/thaw cycles)

Reference Interval

0.0-2.3 ng/mL

Interpretive Data

This assay is performed using the Fujirebio Diagnostics CYFRA 21-1 Enzyme Immunoassay. Results obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Compliance Category

FDA

Note
Hotline History
N/A
CPT Codes

86316

Components
Component Test Code* Component Chart Name LOINC
0081345 CYFRA 21-1, Serum 25390-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • CYFRA 21-1 (Cytokeratin 19 Fragment (CYFRA 21-1), Serum)
  • Soluble Cytokeratin 19 Fragment (Cytokeratin 19 Fragment (CYFRA 21-1), Serum)
CYFRA 21-1 (Cytokeratin 19 Fragment), Serum